2H0 Stock Chart & Stats
€0.77
-€0.03(-2.34%)
At close: 4:00 PM EDT
€0.77
-€0.03(-2.34%)
Day’s Range― - ―
52-Week Range€0.71 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.82M
Enterprise Value€11.54M
Total Cash (Recent Filing)€1.72M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.20
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding6,545,995
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionEliminating debt materially reduces leverage and interest-related pressure compared with prior years. This gives Exicure a cleaner capital structure and avoids debt repayment obligations, although the benefit is limited by continuing losses and a very small equity base.
Improving Loss ProfileLower losses than in 2023–2024 indicate some improvement in the rate of deterioration and could extend available resources if maintained. However, the improvement has not yet produced profitability, revenue, or self-sustaining operations, so the benefit remains conditional.
Proprietary SNA PlatformA proprietary spherical nucleic acid platform provides a defined technology foundation across immuno-oncology and inflammatory disease programs. If clinical development succeeds, a reusable platform could support multiple candidates and partnerships, though current value remains tied to research and clinical execution.
Bears Say
No Commercial RevenueThe absence of commercial revenue means Exicure has not demonstrated product-market monetization or an operating engine that can fund development internally. Persistent gross losses and clinical-stage activity leave future progress dependent on successful programs, collaborations, or additional financing.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the business consumes capital to fund operations rather than generating cash. Continued burn increases the importance of new capital or major spending reductions and can constrain the company’s ability to advance its pipeline.
Equity And Listing RiskSeverely reduced equity and unresolved Nasdaq compliance create a durable financial and corporate-risk overhang. Failure to meet the extension terms could lead to delisting, while efforts to restore compliance may require capital actions that could further pressure existing shareholders.
Exicure News
2H0 FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was €0.70 and its highest was €8.25 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is €5.82M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is Nov 12, 2026 which is in 21 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on Aug 07, 2026. The company reported -€0.157 earnings per share for the quarter.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,545,995 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -€0.157 in its last earnings report. Following the earnings report the stock price went down -13.679%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.